MTOR and prostate carcinoma: Furthermore, the importance of phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling for maintaining the CSC phenotype in renal cell cancer (138), prostate cancer (139), and lung cancer (140) has been confirmed.